Skip to main content

Research Repository

Advanced Search

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer (2020)
Journal Article
Li, L., Hobson, L., Perry, L., Clark, B., Heavey, S., Haider, A., …Ladomery, M. (2020). Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. British Journal of Cancer, 123, 1024-1032. https://doi.org/10.1038/s41416-020-0951-2

Background: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefor... Read More about Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.